TRiCares has started the TRICURE US investigational device exemption pivotal study of its Topaz transcatheter tricuspid valve replacement system.
The prospective, global, multicentre trial will evaluate the safety and effectiveness of Topaz in patients with severe or greater tricuspid regurgitation who are considered suitable for valve replacement.
Participants will be randomised on a one-to-one basis between the device and the study’s control pathway. The programme is expected to involve as many as 75 clinical sites across the United States, Canada, and several European countries.
The first patient was treated at Piedmont Heart Institute in Atlanta. TRICURE is running alongside the company’s continuing European pivotal programme, expanding the clinical evidence required for regulatory review and potential commercial use in additional markets.
Tricuspid regurgitation occurs when the valve between the right atrium and right ventricle does not close effectively, allowing blood to flow backwards. Severe disease can place additional strain on the heart and is associated with fatigue, swelling, reduced physical capacity, and progressive organ complications.
Open surgical treatment can be difficult in patients with advanced disease or additional health conditions. Transcatheter systems are designed to provide an alternative by delivering a repair or replacement device through the vascular system rather than through conventional open-heart surgery.
Topaz uses a self-expanding biological valve held within a two-stent architecture. The system is introduced through the venous circulation and positioned within the native tricuspid anatomy, where it is intended to restore forward blood flow without removing the original valve.
The right side of the heart creates a demanding mechanical environment. The tricuspid annulus can be large and irregular, surrounding tissue may be fragile, and the device operates close to the heart’s electrical conduction system and other critical structures.
A replacement valve must remain stable through repeated cardiac cycles while accommodating movement and changing loads. Its frame, anchoring method, leaflet material, delivery catheter, and release mechanism have to function together across anatomy that varies substantially between patients.
The pivotal study moves Topaz from early feasibility and initial clinical evaluation into a structured programme intended to support regulatory decision-making. Procedural performance, patient outcomes, adverse events, device durability, and consistency across clinical centres will all contribute to the resulting evidence.
Running a trial across as many as 75 sites introduces manufacturing and operational requirements beyond those of an early clinical programme. Larger quantities of devices must be produced under controlled conditions, with traceable materials, validated processes, consistent dimensions, sterile packaging, and documented release testing.
Biological valve manufacture is particularly sensitive to material selection and handling. Tissue preparation, preservation, cutting, assembly, inspection, and storage can affect leaflet performance, while the metallic frame and catheter system require separate forming, joining, finishing, and cleanliness controls.
Every component must fit within a delivery profile suitable for minimally invasive use. Reducing catheter diameter can improve vascular access, but it increases the mechanical demands involved in compressing, retaining, releasing, and accurately deploying the valve.
Device sizing and imaging are equally important because the system has to be matched to the patient before treatment. Clinical teams require reliable methods for assessing anatomy, selecting the correct configuration, planning access, and confirming the final position.
Structural heart development has expanded beyond the aortic valve as manufacturers pursue treatments for mitral and tricuspid disease. Progress has been slower in these areas because the anatomy is less uniform and reliable anchoring or repair can be more difficult to achieve.
Competing approaches include leaflet repair, annuloplasty, complete valve replacement, and systems designed to manage the consequences of regurgitation elsewhere in the venous circulation. Several technologies may eventually coexist, with treatment selected according to anatomy, disease progression, surgical risk, and the condition of the right ventricle.
Pivotal trials also test the manufacturer’s operating model. Training, delivery logistics, inventory management, imaging protocols, device sizing, technical support, and complaint handling must function consistently across an international network of hospitals.
Once a trial is under way, changes to components or production processes have to be tightly controlled. Improvements that reduce cost or increase manufacturing output may still require evidence demonstrating that the revised device remains equivalent to the version evaluated clinically.
TRiCares must therefore expand clinical supply without introducing uncontrolled variation. Its Paris and Munich operations provide a European engineering base, while the multinational programme will produce practical data on device use across different hospitals, clinicians, and patient populations.
Completion of enrolment will be followed by clinical monitoring and analysis, after which any regulatory submission would face a detailed review of performance and manufacturing controls. Reimbursement, physician training, production scale, and long-term evidence would follow before routine commercial adoption.
The opening of TRICURE establishes a defined path through those stages. Topaz now has to demonstrate that its valve architecture, delivery system, production controls, and clinical results remain consistent when transferred from specialist early studies into a large international programme.
